Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female 2 month-old infants (55 - 89 days) on the day of consent.~2. Infants whose parents or legal guardians have voluntary given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.~3. Infants whose parents or legal guardians can comply with study procedures including follow-up~Exclusion Criteria:~1. Previously received any meningococcal A, C, W and Y vaccines.~2. Previous confirmed or suspected disease caused by N. meningitidis or who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection at any time since birth.~3. Progressive, unstable or uncontrolled clinical conditions.~4. A history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component, such as latex allergy.~5. Experienced significant acute or chronic infection within the previous 7 days or have experienced fever (temperature ≥ 38.0°C \[100.4°F\]) within the previous 3 days.~6. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~7. Received treatment with systemic administration corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth~8. Ever received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation (including Hepatitis B immune globulin) at any time since birth and for the full length of the study.~9. Any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw.~10. Any condition which, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.~11. Received or are planning to receive any investigational or non-registered medicinal product from birth and throughout the study.~12. Received oral or parenteral antibiotic treatment in the 3 days prior to the scheduled blood draw (topical antibiotics are acceptable, including antibiotic eye drops).~13. Relatives of site research staff working on this study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- MenACWY Group (Type: EXPERIMENTAL): Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).